<DOC>
	<DOCNO>NCT02985437</DOCNO>
	<brief_summary>Bovine Lung Surfactant use standard therapy reduce alveolar surface tension preterm infant . Here drug administer via airway . The use skin stimulate wound heal yet test human , i.e . yet approve treatment wound heal disorder . In planned clinical trial Lung Surfactant use first time local treatment skin lesion human . No substance relate side effect observe application via airway neonate . The innovative idea use lung surfactant skin wound heal derive two observation . First , skin injure , barrier protect moist body surface dry environment discontinue part lose . Lung surfactant several characteristic might beneficial treatment chronic cutaneous wound .</brief_summary>
	<brief_title>Safety Tolerability Topically Applied Bovine Lung Surfactant Intact Skin</brief_title>
	<detailed_description />
	<mesh_term>Connective Tissue Diseases</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Pulmonary Surfactants</mesh_term>
	<criteria>Two healthy forearm , No known chronical skin disease , Dermatoses allergy , Signed form consent , Caucasian Pregnancy nursing period , Diabetes ( Type I II ) , Systemic infectious disease , Skin disease , Known allergies bovine product wound dressing , Mental diseases , miss ability consent , Addictive disorder ( e.g . alcohol , drug ) , Peripheral circulatory disorder , Morbus Raynaud , Current ( &lt; 4 week ago ) participation clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>wound healing</keyword>
	<keyword>Bovine Lung Surfactant</keyword>
	<keyword>SATOSU</keyword>
</DOC>